Goldman analyst points to Big Pharma durability as rates and politics add uncertainty

Wall Street’s debate over how to position for higher-for-longer interest rates is spilling into pharmaceuticals, with a Goldman Sachs analyst highlighting large drugmakers as potential sources of relative durability in a choppy macro backdrop.

In a market note distributed through Yahoo Finance, Asad Haider said there is still “promise” in Big Pharma and biotech despite two crosscurrents investors are weighing: the impact of rising interest rates and the uncertainty surrounding the US midterm election cycle.

The analyst’s framing centers on the idea that major healthcare companies can offer investors a different risk profile than more rate-sensitive or demand-cycle-exposed sectors, even when markets struggle to price the future path of rates and policy.

Within that “promise” bucket, Haider pointed to Johnson & Johnson, Eli Lilly, and Merck as names he views positively. The post does not detail which specific catalysts or financial line items underpin each pick, nor does it lay out a detailed upside-and-downside valuation case.

For investors, the practical takeaway from the commentary is that the debate is not only about which company has the most exciting pipeline, but also about which business models are likely to remain investable when discount rates and political timelines keep shifting.

Pharmaceuticals have long been treated as more defensive than many other industries because revenue is tied to ongoing medical demand rather than discretionary consumer spending. But the post does not provide additional company-specific support for that general view beyond the analyst’s claim that opportunity remains.

The post also does not specify whether the firms cited are expected to benefit from any near-term policy outcomes or whether the argument is primarily balance-sheet and cash-flow driven versus growth-driven. As a result, readers are left with directional guidance rather than a quantified roadmap.

What to watch next is whether the cited companies report fundamentals that align with the “durability” thesis, such as updates on commercial momentum and pipeline progress. It will also be important to see if other analysts revise their stance as political and rate uncertainty persists.